All In MedTech

Device Trial Radar · NCT06406439

DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients

A Multicenter, Open Label, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen DIA:CONN P8 in Patients With Type 1, Type 2 or Pancreatogenic Diabetes Mellitus Under Multiple Dose Insulin Therapy

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

May 21, 2024

Primary completion

Apr 2, 2025

Study completion Apr 2, 2025

Sponsor

Lead sponsor
G2e Co., LtdNot on our public-company list
Sponsor type
Industry
First posted
May 9, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicenter, Open label, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen DIA:CONN P8 in patients with Type 1, Type 2 or Pancreatogenic Diabetes Mellitus under Multiple Dose Insulin Therapy

Conditions

  • Diabetes (Insulin-requiring, Type 1 or Type 2)
  • Pancreatogenic Diabetes Mellitus

Interventions

  • Smart Insulin PenDevice

    During the 12-week, for basal insulin, the treatment group will input and inject the dosage using the DIA:CONN P8, using only the insulin injection and injection recording functions, same as the blind CGM period. For bolus insulin, when the carbohydrate counting is entered or the type of meal is selected into the DIA:CONN P8 application, the insulin dosage is automatically calculated and set using the entered information and other indicators. Subjects inject the insulin at that calculated dosage using the DIA:CONN P8.

  • Injection of bolus insulin via conventional therapy using insulin penDevice

    During the 12-week, the control group will use DIA:CONN P8 to manually input and inject the dosage of both basal and bolus insulin, only using the insulin injection and injection recording functions, same as the blind CGM period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c(%) at 12 weeks compared to baselineTime frame: from baseline to the 12-week time point

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Chung-Ang University Gwangmyeong Hospital

    Gwangmyeong, Deokan-ro, South Korea

  • Kyung Hee University Hospital

    Seoul, Dongdaemun-gu, South Korea

  • Kyung Hee University Hospital at Gangdong

    Seoul, Gangdong-gu, South Korea

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.